Next Article in Journal
Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective
Next Article in Special Issue
Characterization of the Lytic Capability of a LysK-Like Endolysin, Lys-phiSA012, Derived from a Polyvalent Staphylococcus aureus Bacteriophage
Previous Article in Journal
Biotinylated Chlorin and Its Zinc and Indium Complexes: Synthesis and In Vitro Biological Evaluation for Photodynamic Therapy
Open AccessOpinion

Information Phage Therapy Research Should Report

Department of Microbiology, The Ohio State University, Mansfield, OH 44906, USA
Academic Editor: Jean Jacques Vanden Eynde
Pharmaceuticals 2017, 10(2), 43; https://doi.org/10.3390/ph10020043
Received: 15 April 2017 / Revised: 27 April 2017 / Accepted: 27 April 2017 / Published: 30 April 2017
(This article belongs to the Special Issue Phage Therapy and Phage-Mediated Biological Control)
Bacteriophages, or phages, are viruses which infect bacteria. A large subset of phages infect bactericidally and, consequently, for nearly one hundred years have been employed as antibacterial agents both within and outside of medicine. Clinically these applications are described as phage or bacteriophage therapy. Alternatively, and especially in the treatment of environments, this practice instead may be described as a phage-mediated biocontrol of bacteria. Though the history of phage therapy has involved substantial clinical experimentation, current standards along with drug regulations have placed a premium on preclinical approaches, i.e., animal experiments. As such, it is important for preclinical experiments not only to be held to high standards but also to be reported in a manner which improves translation to clinical utility. Here I address this latter issue, that of optimization of reporting of preclinical as well as clinical experiments. I do this by providing a list of pertinent information and data which, in my opinion, phage therapy experiments ought to present in publications, along with tips for best practices. The goal is to improve the ability of readers to gain relevant information from reports on phage therapy research, to allow other researchers greater potential to repeat or extend findings, to ease transitions from preclinical to clinical development, and otherwise simply to improve phage therapy experiments. Targeted are not just authors but also reviewers, other critical readers, writers of commentaries, and, perhaps, formulators of guidelines or policy. Though emphasizing therapy, many points are applicable to phage-mediated biocontrol of bacteria more generally. View Full-Text
Keywords: bacteriophage therapy; biocontrol; biological control; peer review; phage therapy; pharmacology; preclinical development; publication; regulation bacteriophage therapy; biocontrol; biological control; peer review; phage therapy; pharmacology; preclinical development; publication; regulation
MDPI and ACS Style

Abedon, S.T. Information Phage Therapy Research Should Report. Pharmaceuticals 2017, 10, 43.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop